196 related articles for article (PubMed ID: 25424123)
1. Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy.
Foster CC; Jackson WC; Foster BC; Johnson SB; Feng FY; Hamstra DA
Radiat Oncol; 2014 Nov; 9():245. PubMed ID: 25424123
[TBL] [Abstract][Full Text] [Related]
2. The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer.
Johnson S; Jackson W; Li D; Song Y; Foster C; Foster B; Zhou J; Vainshtein J; Feng F; Hamstra D
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):554-61. PubMed ID: 23561650
[TBL] [Abstract][Full Text] [Related]
3. A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.
Jackson WC; Johnson SB; Li D; Foster C; Foster B; Song Y; Schipper M; Shilkrut M; Sandler HM; Morgan TM; Palapattu GS; Hamstra DA; Feng FY
Radiat Oncol; 2013 Jul; 8():170. PubMed ID: 23835115
[TBL] [Abstract][Full Text] [Related]
4. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
[TBL] [Abstract][Full Text] [Related]
5. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
[TBL] [Abstract][Full Text] [Related]
6. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
[TBL] [Abstract][Full Text] [Related]
7. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
[TBL] [Abstract][Full Text] [Related]
8. Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.
Jackson WC; Suresh K; Tumati V; Dess RT; Soni PD; Zhao SG; Zumsteg ZS; Hannan R; Hollenbeck BK; George A; Kaffenberger SD; Salami SS; Hearn JWD; Morgan TM; Mehra R; Schipper M; Feng FY; Desai NB; Spratt DE
Eur Urol Oncol; 2018 Sep; 1(4):276-282. PubMed ID: 31100248
[TBL] [Abstract][Full Text] [Related]
9. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
[TBL] [Abstract][Full Text] [Related]
10. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
Stenmark MH; Blas K; Halverson S; Sandler HM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e335-44. PubMed ID: 21645976
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):112-8. PubMed ID: 22300563
[TBL] [Abstract][Full Text] [Related]
12. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients.
Mauermann J; Fradet V; Lacombe L; Dujardin T; Tiguert R; Tetu B; Fradet Y
Eur Urol; 2013 Jul; 64(1):19-25. PubMed ID: 22901983
[TBL] [Abstract][Full Text] [Related]
13. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
[TBL] [Abstract][Full Text] [Related]
14. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.
Fu AZ; Tsai HT; Haque R; Ulcickas Yood M; Van Den Eeden SK; Cassidy-Bushrow AE; Zhou Y; Keating NL; Smith MR; Aaronson DS; Potosky AL
World J Urol; 2016 Dec; 34(12):1611-1619. PubMed ID: 27084777
[TBL] [Abstract][Full Text] [Related]
15. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
[TBL] [Abstract][Full Text] [Related]
16. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
18. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH
J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112
[TBL] [Abstract][Full Text] [Related]
19. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
20. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy.
Jackson W; Hamstra DA; Johnson S; Zhou J; Foster B; Foster C; Li D; Song Y; Palapattu GS; Kunju LP; Mehra R; Feng FY
Cancer; 2013 Sep; 119(18):3287-94. PubMed ID: 23821578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
